Vitamin K-absorption From Dairy

NCT00931437 | Completed

• 1 other identifier: 08-3-086
• Study Type: interventional
• Target: 12
• Locations: 1 country
• Sites: 1

Brief Summary

Lactic acid bacteria produce a mixture of higher menaquinones, including menaquinone-9 (MK-9) and menaquinone-10 (MK-10). Vitamin K1 (phylloquinone) is normally present in chloroplasts in green vegetables. A new dairy product is developed containing both vitamin K1 and K2-vitamins. However, the extent to which the various forms of vitamin K are absorbed from such a mixture is not known. In this study the absorption profile of phylloquinone and menaquinones from this new dairy product containing several K-vitamins is investigated. This study describes a dietary intervention experiment for one single cocktail containing several K-vitamins as part of a dairy product.

Conditions

Healthy

Keywords

vitamin K; Bio-availability

Outcome Measures

Primary Outcomes (1)

• serum vitamin K levels: phylloquinone, menaquinone-7,-8,-9,and -10

  one single intake

Secondary Outcomes (1)

• distribution of vitamin K-forms over lipoprotein fractions: triglyceride rich lipoprotein (TGRLP), intermediate-density lipoprotein (IDL), low-density lipoprotein (LDL), high density lipoprotein (HDL) as well as the lipoprotein-free fraction (LPF)

  one single intake

Study Arms (1)

vitamin K-rich dairy product

EXPERIMENTAL

one single intake of a dairy product containing several K-vitamins: phylloquinone, menaquinone-7,8,9-and 10.

Dietary Supplement: vitamin K-rich dairy product

Interventions

vitamin K-rich dairy product DIETARY_SUPPLEMENT

several forms of vitamin K: phylloquinone, menaquinone-7,-8,-9,and -10.

vitamin K-rich dairy product

Eligibility Criteria

• Age: 20 Years - 45 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Healthy men and women between 20 and 45 years old
• Subjects of normal body weight and height according to BMI \< 30
• Subjects of Caucasian race
• Subject has given written consent to take part in the study

You may not qualify if:

• Subjects with (a history of) metabolic or gastrointestinal disease
• Subjects presenting chronic degenerative and/or inflammatory disease
• Abuse of drugs and/or alcohol
• Subjects receiving corticoid treatment
• Subjects using oral anticoagulants

Sponsors & Collaborators

• Maastricht University Medical Center: lead

Study Sites (1)

VitaK BV / University of Maastricht

Maastricht, Netherlands

Location

Study Officials

• Cees Vermeer, PhD

  VitaK / University of Maastricht

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER

Study Record Dates

• First Submitted: June 30, 2009
• First Posted: July 2, 2009
• Study Start: April 1, 2009
• Primary Completion: July 1, 2009
• Study Completion: November 1, 2009
• Last Updated: December 16, 2010

Record last verified: 2010-12

Locations

NL (1)